HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

Roche’s Vabysmo Hits Indian Markets, Making History as the Premier Bispecific mAb for Dual Vision Challenges

NextEdge Admin

14 Mar 2024

2 min 25 sec

Roche Pharma India has entered the field of ophthalmology with the introduction of Vabysmo (faricimab) for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME), prevalent causes of global vision loss. Vabysmo stands out as the inaugural dual-pathway-inhibitor, uniquely addressing two critical disease pathways associated with various sight-threatening retinal conditions. By neutralizing both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), pivotal proteins in retinal condition development, Vabysmo stabilizes blood vessels in the eye and combats vision loss.

Distinguished as the world’s premier bispecific monoclonal antibody (mAb), Vabysmo represents a singular molecule adept at targeting and inhibiting the effects of two crucial factors, offering the combined advantages of two medications in one. In contrast to current treatments exclusively targeting VEGF, Vabysmo introduces a groundbreaking approach by concurrently blocking pathways involving both Ang-2 and VEGF-A. This innovation marks the first new mechanism of action (MoA) in over 15 years for nAMD and nearly a decade for DME, promising to enhance vision outcomes by fortifying blood vessels in the retina.

Having gained approval from the USFDA in January 2022, Vabysmo is now accessible in over 90 countries, with over 2 million doses administered to date. Positioned as a potential game-changer, Vabysmo has the capacity to revolutionize the existing Standard of Care (SoC) by mitigating the burdens associated with current treatment options, such as frequent eye injections and physician visits, which often result in under-treatment and suboptimal vision outcomes.